Alogliptin; a review of a new dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of type 2 diabetes mellitus

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 14, Issue 1, 2014, Pages 64-70

  Said, Sarmad ^a   Nwosu, Azikiwe C ^a   Mukherjee, Debabrata ^a   Hernandez, German T ^a  

^a Texas Tech University Health Sciences Center El Paso   (United States)

Author keywords

Alogliptin; Antihyperglycemic agents; Dipeptidyl peptidase 4 inhibitors; Glucagon like peptide 1; Glucose dependent insulinotropic peptide; Incretins; Type 2 diabetes mellitus

Indexed keywords

ALOGLIPTIN; ALOGLIPTIN PLUS METFORMIN; ALOGLIPTIN PLUS PIOGLITAZONE; GLIPIZIDE; METFORMIN; SITAGLIPTIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; PIPERIDINE DERIVATIVE; URACIL;

ARTICLE; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); DIZZINESS; DRUG EFFICACY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HEADACHE; HEART PROTECTION; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS CANCER; PANCREATITIS; PERIPHERAL EDEMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN DISEASE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; ANALOGS AND DERIVATIVES; ANIMAL; DIABETES MELLITUS, TYPE 2; ENZYMOLOGY;

ANIMALS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; PIPERIDINES; URACIL;

EID: 84905663496     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871529X14666140701095849     Document Type: Article

References (29)

1. International Diabetes Federation (IDF). The Global Burden. http://www.idf.org/diabetesatlas/5e/the-globalburden [Accessed April 5, 2014].
2. Meigs, J.B. Epidemiology of cardiovascular complications in type 2 diabetes mellitus. Acta.Diabetol., 2003, 40(2), 358-361.
3. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. Atlanta: Centers for Disease Control and Prevention. http://www.cdc.gov/diabetes/ pubs/pdf/ndfs_2007.pdf [Accessed on September 23,2013].
4. Kim, W.; Egan, J.M. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol.Rev., 2008, 60, 470-512.
5. Grieve, D.J.; Cassidy, R.S.; Green, B.D. Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?. Br. J.Pharmacol., 2009, 157, 1340-1351.
6. Lovshin, J.A.; Drucker, D.J. Incretin-based therapies for type-2 diabetes mellitus. Nat. Rev.Endocrinol., 2009, 5, 262-269.
7. Mudaliar, S.; Henry, R.R. Theincretin hormones: from scientific discovery to practical therapeutics. Diabetologica, 2012, 55, 1865-1868.
8. Ta, N.N.; Schuyler, C.A.; Li, Y.; Lopes-Virella, M.F.; Huang, Y. DPP-4 (CD26) Inhibitor Alogliptin Inhibits Atherosclerosis in Diabetic Apolipoprotein E-Deficient Mice. Cardiovasc. Pharmacol., 2011, 58, 157-166.
9. DeFronzo, R.A.; Fleck, P.R.; Wilson, C.A.; Mekki, Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized double blind, placebo-controlled study. Diabetes care, 2008, 31, 2315-2317.
10. Bolen, S.; Feldman, L.; Vassy, J.; Wilson, L.; Yeh, H.C.; Marinopoulos, S.; Wiley, C.;Selvin, E.; Wilson, R.; Bass, EB.; Brancati, FL. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann. Intern.Med., 2007, 147, 386-399.
11. Pratley, R.E.; Jauffret-Kamel, S.; Galbreath, E.; Holmes, D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm.Metab. Res., 2006, 38, 423-428.
12. Scott, R.; Wu, M.; Sanchez, M.; Stein, P. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int. J.Clin.Pract., 2007, 61, 171-180.
13. Lee, B.; Shi, L.; Kassel, D.B.; Asakawa, T.; Takeuchi, K.; Christopher, R.J. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys. Eur. J. Pharmacol., 2008, 589, 306-314.
14. White, W.B.; Pratley, R.; Fleck, P. Cardiovascular safety of the dipeptidyl-peptidase-4-inhibitor alogliptin in type-2 diabetes mellitus. Diabetes. Obes. Metab., 2013, 15(7), 668-673.
15. White, W.B.; Cannon, C.P.; Heller, S.R.; Nissen, S.E.; Bergenstal, R.M.; Bakris, G.; Perez, A.; Fleck, P.R.; Mehta, C.; Kupfer, S.; Wilson, C.; Cushman, W.C.; Zannad, F. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. N. Engl. J. Med., 2013, 369(14), 1327-1335.
16. Bao, W.; Morimoto, K.; Hasegawa, T.; Sasaki, N.; Yamashita, T.; Hirata, K.; Okita, Y.; Okada, K. Orally administered dipeptidyl peptidase-4 inhibitor (alogliptin) prevents abdominal aortic aneurysm formation through an antioxidant effect in rats. J. Vasc. Surg., 2013, 13, S0741-5214.
17. Xiong, W.; Mactaggart, J.; Knispel, R.; Worth, J.; Zhu, Z.; Li Y.; Sun, Y.; Baxter, B.T.; Johanning, J. Inhibition of reactive oxygen species attenuates aneurysm formation in a murine model. Atherosclerosis, 2009, 202(1), 128-134.
18. Chinda, K.; Palee, S.; Surinkaew, S.; Phornphutkul, M.; Chattipakorn, S.; Chattipakorn N. Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury. Int. J.Cardiol., 2013, 167(2), 451-457.
19. Sakata, K.; Hayakawa, M.; Yano, Y.; Tamaki, N.; Yokota, N.; Eto, T.; Watanabe, R.; Hirayama, N.; Matsuo, T.; Kuroki, K.; Sagara, S.; Mishima, O.; Koga, M.; Nagata, N.; Nishino, Y.; Kitamura, K.; Kario, K.; Takeuchi, M.; Yamagishi, S.I. Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product - receptor for advanced glycation end product axis, and albuminuria in Japanese type 2 diabetes. Diabetes.Metab. Res. Rev., 2013, 29(8), 624-30.
20. Nauck, M.A.; Ellis, G.C.; Fleck, P.R.; Wilson, C.A.; Mekki, Q. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int. J. Clin. Pract., 2009, 63(1), 46-55.
21. Wu, D.; Li, L.; Liu, C. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as 70 Cardiovascular & Haematological Disorders-Drug Targets, 2014, Vol. 14, No. 1 monotherapy in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes.Obes. Metab., 2014, 16(1), 30-37.
22. Rosenstock, J.; Wilson, C.; Fleck, P. Alogliptin versus glipizidemonotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study. Diabetes, Obesity and Metabolism, 2013, 15, 906-914.
23. Bosi, E.; Ellis, G.C.; Wilson, C.A.; Fleck, P.R. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study. Diabetes, Obesity and Metabolism, 2011, 13, 1088-1096.
24. Elashoff, M.; Matveyenko, A.V.; Gier, B.; Elashoff, R.; Butler, P.C. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology, 2011, 141, 150-156
25. Monami, M.; Dicembrini, I.; Mannucci, E. Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trial. Diabetes Obes. Metab., 2013, 16(1), 48-56.
26. Egan, A.G.; Blind, E.; Dunder, K.; de Graeff, P.A.; Hummer, B.T.; Bourcier, T.; Rosebraugh, C. Pancreatic safety of incretin-based drugs-FDA and EMA assessment. N. Engl. J. Med., 2014, 370(9), 794-797.
27. Nakamura, Y.; Inagaki, M.; Shimizu, T.; Fujita, K.; Inoue, M.; Gotoh, H.; Oguchi, K.; Goto, Y. Long-Term Effects of Alogliptin Benzoate in Hemodialysis Patients with Diabetes: A 2-year Study. Nephron.Clin.Pract., 2013, (123), 46-51.
28. Pratley, R.E.; Reusch, J.E.; Fleck, P.R.; Wilson, C.A.; Mekki, Q. Alogliptin Study 009 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr. Med. Res. Opin., 2009, (25), 2361-2371.
29. Rosenstock, J.; Inzucchi, S.E.; Seufert, J.; Fleck, P.R.; Wilson, C.A.; Mekki, Q. Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes. Diabetes Care, 2010, (33), 2406-2408.